eculizumab Articles
News briefs: Grunenthal adds to portfolio; Ajinomoto to buy Althea; Alexion's Soliris OKed in Canada
6 March 2013
Alexion's Soliris reduces hemolysis in PNH
8 June 2009
Alexion submits Soliris NDA in Japan
16 April 2009
Alexion gets approval for Soliris in Australia
9 March 2009
Japan orphan status for Alexion's Soliris
19 January 2009
Stock Commentary - New York week to Jan 5, 2009
12 January 2009
Alexion's Soliris improves PNH fatigue
23 June 2008
Alexion gains rights to Soliris-related patents for $10M
25 February 2008
Japan urges orphan, painkillers development
21 November 2007
Alexion's Soliris gets EU OK for PNH
16 July 2007
Soliris works across all PNH patient subgroups
18 June 2007
Positive CHMP opinion for Soliris
7 May 2007
FDA accepts Alexion's Soliris BLA
20 November 2006
Alexion's submits Soliris MAA to EMEA
2 October 2006
Alexion submits Soliris BLA to FDA
25 September 2006
Alexion's Soliris fares well in Ph III PNH trial
19 June 2006
Alexion reports strong Ph III eculizumab data
6 February 2006
Alexion: randomization in eculizumab trial complete
8 August 2005
Positive data for Alexion's PNH therapy
4 July 2005
Alexion's 3rd-qtr loss leaps on soaring costs
13 June 2005
Alexion's eculizumab bolstered by study
30 May 2005
Alexion 1st-qtr sales flat but expenses rise
13 December 2004
Alexion's eculizumab begins PNH Ph III trial
8 November 2004
Alexion's fiscal-2004 net loss down 12%
4 October 2004
Alexion's eculizumab to enter Phase III for PNH
26 July 2004
Alexion eculizumab trial in RA fully enrolled
10 February 2003
Lonza to manufacture antibody candidate for Alexion
13 January 2003
Alexion completes enrollment in Ph II kidney disease trial
25 February 2002
Showing 1-33 of 33 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
